AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23808255 — intervention group
Group type: COMPARATOR
Intervention: Parenteral feeding
Number of subjects: 40
Study 21680040 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes-specific formula (DSF) - Diasip(®) 2×200mL/day
Number of subjects: 44
Study 21680040 — intervention group
Group type: COMPARATOR
Intervention: Standard, fiber-containing formula
Number of subjects: 44
Study 21680040 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes-specific formula (DSF) - Diasip(®)
Number of subjects: 44
Study 18665366 — intervention group
Group type: EXPERIMENTAL
Intervention: MSCT‐AG
Number of subjects: 15
Study 18665366 — intervention group
Group type: COMPARATOR
Intervention: MR‐AG
Number of subjects: 15
Study 18665366 — intervention group
Group type: EXPERIMENTAL
Intervention: MSCT‐AG and MR‐AG
Number of subjects: 15
Study 17044400 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzzy discrete event system regimen selection
Number of subjects: 35
Study 15242140 — intervention group
Group type: EXPERIMENTAL
Intervention: HSCL-D-13
Number of subjects: 656
Study 15242140 — intervention group
Group type: EXPERIMENTAL
Intervention: HSCL-D-20
Number of subjects: 656
Study 11010932 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher fruit and vegetable intake (quintiles: 2.6, 4.1, 5.5, 7.1, and 10.2 servings/day)
Number of subjects: 39876
Study 11010932 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher fruit and vegetable intake (after excluding participants with diabetes, hypertension, or high cholesterol)
Number of subjects: 39876
Study 11010932 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher fruit and vegetable intake
Number of subjects: 39876
Study 9162510 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 0
Study 9162510 — intervention group
Group type: COMPARATOR
Intervention: Extended field radiotherapy
Number of subjects: 0
Study 8378158 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbitol gum chewing initiated after 5 min
Number of subjects: 5
Study 8378158 — intervention group
Group type: COMPARATOR
Intervention: Sorbitol gum chewing initiated after 15 min
Number of subjects: 5
Study 3517890 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg pyritinol three times daily
Number of subjects: 50
Study 3517890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 29102514 — intervention group
Group type: EXPERIMENTAL
Intervention: omalizumab 300 mg
Number of subjects: 105
Study 29102514 — intervention group
Group type: EXPERIMENTAL
Intervention: omalizumab 150 mg
Number of subjects: 105
Study 29102514 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 105
Study 29102514 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 105
Study 26505573 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical Input (CI)
Number of subjects: 80
Study 26505573 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite Variability Index (CVI)
Number of subjects: 80
Study 26505573 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS and CCS
Number of subjects: 80
Study 26505573 — intervention group
Group type: EXPERIMENTAL
Intervention: CI and CCS
Number of subjects: 80
Study 25487196 — intervention group
Group type: EXPERIMENTAL
Intervention: Wood smoke exposure (1 mg/m³ particulate matter concentration)
Number of subjects: 16
Study 25487196 — intervention group
Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 16
Study 25487196 — intervention group
Group type: EXPERIMENTAL
Intervention: Wood smoke exposure
Number of subjects: 16
Study 21838788 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted dosing algorithm for HDMTX based on 24 h MTX plasma concentrations.
Number of subjects: 131
Study 21838788 — intervention group
Group type: COMPARATOR
Intervention: Standard MTX dose (not explicitly detailed in the abstract).
Number of subjects: 131
Study 21838788 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted dose (based on dosing algorithm).
Number of subjects: 131
Study 19961836 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine (an indirect DA agonist)
Number of subjects: 0
Study 19961836 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (DA D2 receptor antagonist)
Number of subjects: 0
Study 19961836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18316153 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric handgrip exercise at 1%, 15%, and 25% of maximum voluntary contraction (MVC)
Number of subjects: 24
Study 18316153 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric handgrip exercise
Number of subjects: 24
Study 15627855 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT-A) - 25 sessions
Number of subjects: 72
Study 15627855 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT-B) - after contact control period
Number of subjects: 72
Study 15627855 — intervention group
Group type: COMPARATOR
Intervention: Contact Control Group (CCG)
Number of subjects: 72
Study 15627855 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT-A)
Number of subjects: 72
Study 15627855 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT-B)
Number of subjects: 72
Study 12798827 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularisation in addition to optimal medical therapy (ACE inhibitors, beta-blockers, aldosterone antagonists, anti-thrombotic agent)
Number of subjects: 800
Study 12798827 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy (ACE inhibitors, beta-blockers, aldosterone antagonists, anti-thrombotic agent) without revascularisation
Number of subjects: 800
Study 10577695 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 Gy x 1
Number of subjects: 1171
Study 10577695 — intervention group
Group type: COMPARATOR
Intervention: 4 Gy x 6
Number of subjects: 1171
Study 9127689 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive ductal carcinoma
Number of subjects: 20
Study 9127689 — intervention group
Group type: COMPARATOR
Intervention: Fibroadenoma
Number of subjects: 20
Study 9127689 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjacent breast stroma of invasive ductal carcinoma
Number of subjects: 20
Study 9127689 — intervention group
Group type: COMPARATOR
Intervention: Adjacent breast stroma of fibroadenoma
Number of subjects: 20
Study 1833121 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (100 mg three times a day for 6 weeks)
Number of subjects: 14
Study 1833121 — intervention group
Group type: COMPARATOR
Intervention: Placebo (three times a day for 6 weeks)
Number of subjects: 14
Study 1833121 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (first treatment)
Number of subjects: 14
Study 1833121 — intervention group
Group type: COMPARATOR
Intervention: Placebo (first treatment)
Number of subjects: 14
Study 1833121 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (second treatment)
Number of subjects: 14
Study 1833121 — intervention group
Group type: COMPARATOR
Intervention: Placebo (second treatment)
Number of subjects: 14
Study 6341844 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg with meals and at bedtime)
Number of subjects: 101
Study 6341844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 6341844 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid (15 ml one hour after meals and at bedtime)
Number of subjects: 101
Study 6341844 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine and Antacid
Number of subjects: 101
Study 30924402 — intervention group
Group type: EXPERIMENTAL
Intervention: CRCS information plus a photo and text narrative of a CRC survivor
Number of subjects: 477
Study 30924402 — intervention group
Group type: EXPERIMENTAL
Intervention: CRCS information plus a photo and text narrative of a CRC screener who did not have cancer
Number of subjects: 477
Study 30924402 — intervention group
Group type: COMPARATOR
Intervention: CRCS information only
Number of subjects: 477
Study 29119807 — intervention group
Group type: EXPERIMENTAL
Intervention: Beliefs About Medication Scale (BAMS)
Number of subjects: 76
Study 29119807 — intervention group
Group type: EXPERIMENTAL
Intervention: Intent to adhere (IA)
Number of subjects: 76
Study 26647918 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 24
Study 26647918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 23609584 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling therapy
Number of subjects: 120
Study 23609584 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dry needling)
Number of subjects: 120
Study 22077915 — intervention group
Group type: EXPERIMENTAL
Intervention: Calen (7 days)
Number of subjects: 106
Study 22077915 — intervention group
Group type: EXPERIMENTAL
Intervention: Calen (14 days)
Number of subjects: 106
Study 22077915 — intervention group
Group type: EXPERIMENTAL
Intervention: Calen/camphorated paramonochlorophenol (CMCP) (7 days)
Number of subjects: 106
Study 22077915 — intervention group
Group type: EXPERIMENTAL
Intervention: Calen/CMCP (14 days)
Number of subjects: 106
Study 22077915 — intervention group
Group type: EXPERIMENTAL
Intervention: Calen/0.4% chlorhexidine (CHX) (7 days)
Number of subjects: 106
Study 22077915 — intervention group
Group type: EXPERIMENTAL
Intervention: Calen/0.4% CHX (14 days)
Number of subjects: 106
Study 22077915 — intervention group
Group type: EXPERIMENTAL
Intervention: Calen/1% CHX (7 days)
Number of subjects: 106
Study 22077915 — intervention group
Group type: EXPERIMENTAL
Intervention: Calen/1% CHX (14 days)
Number of subjects: 106
Study 22077915 — intervention group
Group type: COMPARATOR
Intervention: Chemo‐mechanical preparation with no medication
Number of subjects: 106
Study 22077915 — intervention group
Group type: COMPARATOR
Intervention: No chemo‐mechanical preparation and no medication
Number of subjects: 106
Study 19170903 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated bipolar RV leads
Number of subjects: 292
Study 19170903 — intervention group
Group type: COMPARATOR
Intervention: Integrated bipolar RV leads
Number of subjects: 292
Study 19170903 — intervention group
Group type: EXPERIMENTAL
Intervention: Both lead types
Number of subjects: 292
Study 17255739 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir (LPV/r) 533 mg/133 mg twice daily + efavirenz (EFV) 600 mg once daily
Number of subjects: 236
Study 17255739 — intervention group
Group type: COMPARATOR
Intervention: EFV + two nucleoside reverse transcriptase inhibitors (NRTI)
Number of subjects: 236
Study 17255739 — intervention group
Group type: EXPERIMENTAL
Intervention: LPV/r + EFV
Number of subjects: 236
Study 17255739 — intervention group
Group type: COMPARATOR
Intervention: EFV + NRTI
Number of subjects: 236
Study 15963081 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.d.
Number of subjects: 40
Study 15963081 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg t.d.s. with Omeprazole
Number of subjects: 40
Study 15963081 — intervention group
Group type: COMPARATOR
Intervention: Placebo-matching tegaserod t.d.s.
Number of subjects: 40
Study 14581667 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane at 1.5 MAC
Number of subjects: 16
Study 14581667 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane at 2 MAC
Number of subjects: 16
Study 14581667 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 16
Study 10235417 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg pantoprazole
Number of subjects: 12
Study 10235417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8946232 — intervention group
Group type: EXPERIMENTAL
Intervention: rHu‐EPO (one year)
Number of subjects: 37
Study 8946232 — intervention group
Group type: EXPERIMENTAL
Intervention: rHu‐EPO (two years)
Number of subjects: 37
Study 8946232 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 37
Study 1958158 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intensive group cognitive behavioural therapy (2 days)
Number of subjects: 97
Study 1958158 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 97
Study 6120011 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG feedback
Number of subjects: 160
Study 6120011 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive monitoring training
Number of subjects: 160
Study 6120011 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic desensitization
Number of subjects: 160
Study 6120011 — intervention group
Group type: EXPERIMENTAL
Intervention: High expectancy discussion group
Number of subjects: 160
Study 6120011 — intervention group
Group type: COMPARATOR
Intervention: Waiting list controls
Number of subjects: 160
Study 31690988 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide 1.8 mg once daily for 26 weeks
Number of subjects: 50
Study 31690988 — intervention group
Group type: COMPARATOR
Intervention: placebo for 26 weeks
Number of subjects: 50
Study 31690988 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide
Number of subjects: 50
Study 31690988 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 50
Study 31187612 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal block with analgosedation (group CB)
Number of subjects: 40
Study 31187612 — intervention group
Group type: COMPARATOR
Intervention: General endotracheal anaesthesia (group GA)
Number of subjects: 40
Study 29282075 — intervention group
Group type: EXPERIMENTAL
Intervention: OxCAP-MH
Number of subjects: 172
Study 26350816 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme A (CoA) 400 U/d
Number of subjects: 216
Study 26350816 — intervention group
Group type: COMPARATOR
Intervention: pantethine 600 U/d
Number of subjects: 216
Study 23334063 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate nostril yoga breathing for 10 minutes
Number of subjects: 90
Study 23334063 — intervention group
Group type: COMPARATOR
Intervention: Breath awareness for 10 minutes
Number of subjects: 90
Study 23334063 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (reading a magazine)
Number of subjects: 90
Study 21333060 — intervention group
Group type: EXPERIMENTAL
Intervention: AeroEclipse breath-actuated nebulizer
Number of subjects: 149
Study 21333060 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (small-volume nebulizer or 1-hour continuous nebulization)
Number of subjects: 149
Study 19244376 — intervention group
Group type: EXPERIMENTAL
Intervention: Bread fortified with 125 microg (5000 IU) vitamin D(3) per daily serving
Number of subjects: 45
Study 17132479 — intervention group
Group type: EXPERIMENTAL
Intervention: Site-specific rectocele repair augmented with a porcine small intestinal submucosa graft
Number of subjects: 106
Study 17132479 — intervention group
Group type: EXPERIMENTAL
Intervention: Site-specific rectocele repair
Number of subjects: 106
Study 17132479 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior colporrhaphy
Number of subjects: 106
Study 17132479 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including graft augmentation, site-specific repair, and posterior colporrhaphy)
Number of subjects: 106
Study 17132479 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 106
Study 12767421 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 40 mg
Number of subjects: 270
Study 12767421 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg/ER niacin 2 g
Number of subjects: 270
Study 12767421 — intervention group
Group type: COMPARATOR
Intervention: ER niacin 2 g
Number of subjects: 270
Study 12767421 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 40 mg/ER niacin 1 g
Number of subjects: 270
Study 12767421 — intervention group
Group type: COMPARATOR
Intervention: rosuvastatin alone
Number of subjects: 270
Study 10650230 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac ophthalmic solution
Number of subjects: 49
Study 10650230 — intervention group
Group type: COMPARATOR
Intervention: Control vehicle drops
Number of subjects: 49
Study 9579961 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg GBP oral dose in fasting state
Number of subjects: 12
Study 9579961 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg GBP oral dose in fasting state
Number of subjects: 12
Study 9579961 — intervention group
Group type: COMPARATOR
Intervention: 400 mg GBP oral dose after a high-protein meal
Number of subjects: 12
Study 9579961 — intervention group
Group type: COMPARATOR
Intervention: 800 mg GBP oral dose after a high-protein meal
Number of subjects: 12
Study 8400077 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulosic membranes (CUP)
Number of subjects: 0
Study 8400077 — intervention group
Group type: COMPARATOR
Intervention: Noncellulosic membranes (PAN, AN69)
Number of subjects: 0
Study 8400077 — intervention group
Group type: COMPARATOR
Intervention: Noncellulosic membranes (AN69)
Number of subjects: 0
Study 3081081 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 37
Study 3081081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 29049890 — intervention group
Group type: EXPERIMENTAL
Intervention: Everyday Activity Supports You intervention (group-based intervention focusing on reducing sedentary behaviour, 6 months duration, nine 2-hour sessions)
Number of subjects: 20
Study 29049890 — intervention group
Group type: COMPARATOR
Intervention: Control group (monthly group-based health-related education sessions, 6 months duration, six 1-hour sessions)
Number of subjects: 20
Study 25904498 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05% ointment (CP)
Number of subjects: 48
Study 25904498 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate 0.1% ointment (MMF)
Number of subjects: 48
Study 25232073 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate weight-bearing from day one
Number of subjects: 30
Study 25232073 — intervention group
Group type: COMPARATOR
Intervention: Non-weight-bearing for six weeks
Number of subjects: 30
Study 22421983 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 treatment for 48 hours
Number of subjects: 11
Study 22421983 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 11
Study 19962701 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10mg/day
Number of subjects: 60
Study 19962701 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 19962701 — intervention group
Group type: COMPARATOR
Intervention: allopurinol 300mg/day
Number of subjects: 60
Study 18697846 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted randomization scheme
Number of subjects: 24
Study 18697846 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratification and restriction
Number of subjects: 24
Study 18697846 — intervention group
Group type: EXPERIMENTAL
Intervention: Random allocation process
Number of subjects: 24
Study 16670027 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider education and fee-for-service reimbursement for delivering fluoride varnish and sealants
Number of subjects: 689
Study 16670027 — intervention group
Group type: COMPARATOR
Intervention: Control group (no provider education and fee-for-service reimbursement)
Number of subjects: 689
Study 12826783 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/benazepril 5/10 mg (combination)
Number of subjects: 214
Study 12826783 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10 mg (conventional)
Number of subjects: 214
Study 12826783 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/benazepril (without HCTZ)
Number of subjects: 214
Study 12826783 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (with HCTZ)
Number of subjects: 214
Study 10982310 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg PGE1 alone
Number of subjects: 116
Study 10982310 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg PGE1 plus 1 mg PHE
Number of subjects: 116
Study 8782726 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat diet ad libitum
Number of subjects: 66
Study 8782726 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate aerobic exercise
Number of subjects: 66
Study 8782726 — intervention group
Group type: COMPARATOR
Intervention: Control (no weight change)
Number of subjects: 66
Study 1627943 — intervention group
Group type: EXPERIMENTAL
Intervention: Great-dose huanshao dan capsules
Number of subjects: 309
Study 1627943 — intervention group
Group type: COMPARATOR
Intervention: Great-dose watered pills
Number of subjects: 309
Study 1627943 — intervention group
Group type: COMPARATOR
Intervention: Small-dose watered pills
Number of subjects: 309
Study 1627943 — intervention group
Group type: COMPARATOR
Intervention: Short-treating course group
Number of subjects: 309
Study 1627943 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 6)
Number of subjects: 309
Study 1627943 — intervention group
Group type: EXPERIMENTAL
Intervention: Huanshao dan and watered pills (combined)
Number of subjects: 309
Study 6370979 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomifensine (100 mg single daily dose)
Number of subjects: 100
Study 6370979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 29941021 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluralaner spot-on treatment (Bravecto®) at a dose rate of 40 mg/kg, administered topically on Day 0.
Number of subjects: 20
Study 29941021 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment).
Number of subjects: 20
Study 27386742 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (received five in-school sessions)
Number of subjects: 1381
Study 27386742 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 1381
Study 27386742 — intervention group
Group type: COMPARATOR
Intervention: Control group (received no smoking prevention information)
Number of subjects: 1381
Study 24714829 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine alone
Number of subjects: 120
Study 24714829 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine plus vitamin A plus zinc
Number of subjects: 120
Study 24714829 — intervention group
Group type: COMPARATOR
Intervention: Placebo (zinc plus vitamin A vehicle plus glycine)
Number of subjects: 120
Study 24714829 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine alone and all combined nutrients (glutamine, vitamin A, and zinc)
Number of subjects: 120
Study 24714829 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine treatment
Number of subjects: 120